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Transient receptor potential vanilloid 1 (TRPV1) is widely distributed in the central
nervous system (CNS) including hippocampus, and regulates the balance of excitation and
inhibition in CNS, which imply its important role in epilepsy. We used both pharmacological
manipulations and transgenic mice to disturb the function of TRPV1 and then studied
the effects of these alterations on the susceptibility of pentylenetetrazol (PTZ)-induced
seizures. Our results showed that systemic administration of TRPV1 agonist capsaicin
(CAP, 40mg/kg) directly induced tonic-clonic seizures (TCS) without PTZ induction. The
severity of seizure was increased in lower doses of CAP groups (5 and 10mg/kg), although
the latency to TCS was delayed. On the other hand, systemic administration of TRPV1
antagonist capsazepine (CPZ, 0.05 and 0.5mg/kg) and TRPV1 knockout mice exhibited
delayed latency to TCS and reduced mortality. Furthermore, hippocampal administration of
CPZ (10 and 33 nmol/μL/side) was firstly reported to increase the latency to TCS, decrease
the maximal grade of seizure and mortality. It is worth noting that decreased susceptibility
of PTZ-induced seizures was observed in hippocampal TRPV1 overexpression mice and
hippocampal CAP administration (33 nmol/μL/side), which is opposite from results of
systemic agonist CAP. Our findings suggest that the systemic administration of TRPV1
antagonist may be a novel therapeutic target for epilepsy, and alteration of hippocampal
TRPV1 function exerts a critical role in seizure susceptibility.
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INTRODUCTION
Epilepsy is characterized by the imbalance between excitation
and inhibition of central nervous system (CNS) (Engel, 1996;
Stafstrom, 2003), affecting 1–3% of the worldwide population
(Bhalla et al., 2012). Current prescribed anti-epileptic drugs
(AED) are not effective in all individuals with epilepsy (Fu et al.,
2009; Hu et al., 2012), thus it is necessary to find novel therapeutic
targets for epilepsy. Previous studies have showed that ion chan-
nels play pivotal roles in epilepsy, and most of them have focused
on the selective ion channels such as sodium and potassium chan-
nels (Armijo et al., 2005; Lerche et al., 2013). However, little
attention has been paid to the role of non-selective ion channels
in epilepsy, which may have fewer side effects than the selective
ion channels.
Transient receptor potential vanilloid 1 (TRPV1), the subfam-
ily vanilloid member 1 (Ramsey et al., 2006), is a ligand-gated
non-selective cation channel with high calcium permeability
(Pedersen et al., 2005). It is well-known that TRPV1 is widely
expressed in both rodents and human CNS including hippocam-
pus (Mezey et al., 2000; Cristino et al., 2006; Menigoz and
Boudes, 2011), which is often the focus of epileptic seizures
(Passouant and Cadilhac, 1960; Stafstrom, 2003). Activation of
TRPV1 was found to inhibit calcium influx and reduce GABA
release in synaptosomal hippocampus preparations, thus increase
the excitability of innervated pyramidal cells (Kofalvi et al., 2006;
Gibson et al., 2008). In contrast, activation of presynaptic TRPV1
inhibited CA1 pyramidal neurons via increasing GABA output
(Al-Hayani et al., 2001; Kofalvi et al., 2006). Taken together, these
results imply that hippocampal TRPV1 may play an important
role in epilepsy (Fu et al., 2009). However, the function of hip-
pocampal TRPV1 in epileptogenesis in vivo has not been reported
systematically.
It has been reported that agonist of TRPV1 enhanced
but antagonist suppressed epileptiform activity (Gonzalez-Reyes
et al., 2013) and hyper-excitability in hippocampus (Chen et al.,
2007; Bhaskaran and Smith, 2010). In addition, TRPV1 ago-
nist capsaicin (CAP) exhibited pro-convulsant activity, which
could be blocked by the antagonist capsazepine (CPZ), and CPZ
was able to prevent PTZ-induced seizures (Manna and Umathe,
2012). A recent study has reported that the severity of PTZ-
induced seizures was decreased in TRPV1 deficiency mice (Kong
et al., 2014). Furthermore, significantly increased expression of
TRPV1 was found in the hippocampus and cortex of rodents
and patients with temporal lobe epilepsy (Bhaskaran and Smith,
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2010; Sun et al., 2013). The above studies suggest that TRPV1
activation may accelerate epileptogenesis, while the antagonists of
TRPV1 may be the potential AED (Fu et al., 2009). Inconsistent
with the antagonist results, piperine as an agonist of TRPV1 was
reported to exert anti-seizure effect (Chen et al., 2013; Khom
et al., 2013). Lee et al. also has found that CAP prevents kainic
acid-induced epileptogenesis in mice (Lee et al., 2011). Thus, a
systematic investigation is necessary to elucidate the effects of
agonist and antagonist of TRPV1 on epileptogenesis and to clarify
the opposite effects of CAP on epileptogenesis in previous reports.
Therefore, we studied the systemic effects of the TRPV1 ago-
nist and antagonist on PTZ-induced seizures in a dose dependent
manner. And we further evaluated PTZ-induced seizures in trans-
genic mice including TRPV1 knockout and hippocampal TRPV1
overexpression mice. Then, to clarify the function of hippocam-
pal TRPV1 on epilepsy, the agonist and antagonist of TRPV1 were
administrated into hippocampus respectively to detect the effects
on PTZ-induced seizures. To the best of our knowledge, this is the
first study to investigate the role of hippocampal TRPV1 in epilep-
togenesis in vivo using pharmacological strategies combined with
genetic modified mice.
MATERIALS AND METHODS
ANIMALS
All procedures and animal care were approved by the Animal
Research Committees of the Kunming Institute of Zoology,
Chinese Academy of Sciences, China. Animals were group-housed
(4–5 animals per cage) in clear plastic cages under standard labo-
ratory conditions that included a thermo-regulated temperature
(22–24◦C), 50% humidity, and a 12-h dark/ light cycle with
free access to water and food. All behavioral experiments were
performed between 10:00 and 17:00.
Adult male Kunming mice weighing 25–30 g and Sprague-
Dawley (SD) rats weighing 250–300 g were used (Animal House
Center, Kunming Medical College, Yunnan, China). TRPV1
knockout mice (Caterina et al., 2000) were obtained from the
Model Animal Research Center (Nanjing University, Jiangsu,
China), and matings between TRPV1 heterozygous mice pro-
duced offspring with expected Mendelian distributions of gender
and genotype. Hippocampal TRPV1 overexpression mice were
generated by crossing ROSA-stop flox-TRPV1-IRES-ECFP (here-
after called ROSA-TRPV1) mice (Arenkiel and Klein, 2008) to
heterozygous Cre transgenic mice, T29-1, which are able to
mediate Cre/loxP recombination exclusively in the hippocam-
pal CA1 pyramidal cells (Tsien et al., 1996). ROSA-TRPV1 mice
were obtained from the Jackson Laboratory (the stock number:
008513), and the Cre transgenic mice (hereafter called CA1-Cre)
were obtained from the Model Animal Research Center (Nanjing
University, Jiangsu, China). All mice were weaned on postnatal
day 21 (P21).
DRUGS
Pentylenetetrazol (PTZ), ethosuximide (ESM), capsaicin (CAP),
and capsazepine (CPZ) (Sigma Aldrich, St. Louis, USA) were
freshly prepared prior to use. PTZ and ESM were dissolved in
saline. CAP and CPZ were dissolved in a 1:1:8 mixture of Tween
80: ethanol: saline.
For the control (vehicle) group, animals received vehicle
(1mL/kg, i.p.), which is a 1:1:8 mixture of Tween 80: ethanol:
saline. For the positive control group, animals received ESM
(625mg/kg, i.p.). For the test groups, mice were respectively
injected with CAP (5, 10, and 40mg/kg, i.p.) and CPZ (0.05,
0.5, and 1mg/kg, i.p.). Animals received intra-hippocampal
(i.h.) injections of 1μL per side of ESM (200 nmol/μL/side),
CAP (10, 33, and 100 nmol/μL/side), and CPZ (10, 33, and
100 nmol/μL/side) respectively. Thirty minutes later all animals
were injected with PTZ (60mg/kg, s.c.).
PTZ-INDUCED SEIZURES
Animals were placed individually in Plexiglas boxes and
seizure behaviors were observed for 30min after PTZ injection
(60mg/kg, s.c.). The seizure intensity was evaluated as follows
(Racine, 1972; Hansen et al., 2012): Stage 0, no response; Stage
1, ear and facial twitching; Stage 2, myoclonic jerks, convulsive
waves through the body; Stage 3, clonic convulsion with forelimb
clonus and rearing; Stage 4, clonic seizure with rolling over into a
side position side position, loss of postural control; Stage 5, gen-
eralized tonic-clonic seizures (TCS), tonic extension episode and
status epilepticus; and Stage 6, death within 30min. Latency to the
onset of TCS, the maximal seizure score (obtained during 30min
for rats; obtained in 5-min blocks during 30min for mice), and
the number of mortality were measured. The maximal latency
was taken as 1800 s if no signs of seizures were observed during
30min.
CANNULA IMPLANTATION
Rats were anesthetized with pentobarbital sodium (80mg/kg,
i.p.). A guide cannula (22 gauge) was stereotaxically implanted
in the CA1 region of hippocampus at coordinates AP-3.8, Lat. ±
2.8, DV 2.5 of the atlas of Paxinos and Watson (1986). The guide
cannula were fixed with dental cement for which three small skull
screws (1mm) were previously screwed into the skull as anchors.
Animals were then allowed to recover for one week. Drugs were
administered with a microinjector connected to an internal can-
nula by polyethylene tubing, and a volume of 1μL per side was
administered over a period of 8min. The volume of 1μL per side
injected into hippocampus is usually used in previous studies (Li
et al., 2008; Mitsushima et al., 2013). The cannula was left in the
place for a further 2min before being slowly withdrawn to avoid
back flow.
THE CONFIRMATION OF INJECTED LOCATION IN HIPPOCAMPUS WITH
TRYPANBLUE STAINING
After finishing all the experiments, a volume of 1μL per side
trypanblue was administered in the implanted rat hippocam-
pus as the methods mentioned above. Then the rats were deeply
and fast anesthetized by diethyl ether, and their brains were dis-
sected in cold 0.01M phosphate buffered saline (PBS; pH 7.4).
Four hundred-μm brain sections were cut, and the images were
captured using a stereoscopic microscope (Leica).
GENOTYPING ASSAY
Genomic DNA was extracted by the TIAN quick Midi
Purification kit (Tiangen Biotech (Beijing) CO., LTD. DP 204-
0F3). The targeted lines of DNA from the specific transgenic
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mice were detected by polymerase chain reaction (PCR). The spe-
cific primers sequences of the DNA from TRPV1 knockout mice,
CA1-Cre mice and ROSA-TRPV1 mice were shown as follows:
TRPV1-Wild type Forward: CCTGCTCAACATGCTCATTG
TRPV1-Common: TCCTCATGCACTTCAGGAAA
TRPV1-Mutant Forward: CACGAGACTAGTGAGACGTG
Product length = 984 bp (wild type) or 600 bp (mutant)
Cre-Forward: TCGATGCAACGAGTGATGAG
Cre-Reverse: TCCATGAGTGAACGAACCTG
Product length = about 300–400 bp
ROSA-TRPV1-Wild type Forward: TCCCAAAGTCGCTCT
GAGTT
ROSA-TRPV1-Common: ACTCGGGTGAGCATGTCTTT
ROSA-TRPV1-Mutant Forward: GCATGGACGAGCTGT
ACAAG
Product length = 486 bp (wild type) or 600 bp (mutant)
The information of TRPV1 and ROSA-TRPV1 primers were
obtained from Jackson Laboratory.
REVERSE TRANSCRIPTION PCR (RT-PCR) ASSAY
The hippocampal tissues of TRPV1 knock out mice and hip-
pocampal TRPV1 overexpression mice were immediately isolated
on ice after diethyl ether anesthesia. Thirty minutes after PTZ-
induction (60mg/kg, s.c.), the hippocampal tissues of the mice
were immediately isolated on ice after diethyl ether anesthesia.
Total RNA was extracted from hippocampal tissues of mice using
RNA simple Total RNA kit (Tiangen Biotech (Beijing) CO., LTD.
DP 419). And then the cDNA was synthesized by the Prime
Script™ Reverse Transcriptase Reagent kit (Takara, RR037A),
which was performed according to the manufacturer’s instruc-
tions. The relative mRNA expression level of TRPV1 was mea-
sured by RT-PCR. The background density was subtracted from
the TRPV1 band density and normalized to β-actin, which was
used as the loading control gene. The specific primers sequences
of TRPV1 and β-actin were displayed as follows:
TRPV1-Forward: GGGTCATTTCTCCCCTACGC
TRPV1-Reverse: CGTAGCAACACCAGCCCAA
Product length = 415 bp
Actin-Forward: CATCCGTAAAGACCTCTATGCCAAC
Actin-Reverse: ATGGAGCCACCGATCCACA
Product length = 171 bp
STATISTICAL ANALYSIS
All data were expressed as the mean ± SEM. All statistical anal-
yses were carried out by using SPSS 16.0. Comparison between
two groups was conducted by unpaired Student’s t-test, compari-
son among more than two groups was made by One-Way analysis
of variance (ANOVA) followed by the least significant difference
(LSD) test, and the development of seizure score was analyzed
by using a repeated measure ANOVA test. The differences were
considered statistically significant if p < 0.05.
RESULTS
THE EFFECTS OF SYSTEMIC ADMINISTRATION OF AGONIST AND
ANTAGONIST OF TRPV1 ON PTZ-INDUCED SEIZURES
As a non-competitive antagonist of GABAA receptor,
pentylenetetrazol (PTZ) is often used to induce tonic-clonic
seizures (TCS) in the animal model of epilepsy (Olsen, 1981;
Dhir, 2012). We administrated the agonist and antagonist of
TRPV1 respectively 30min before PTZ (s.c. 60mg/kg) injection.
Ethosuximide (ESM, 625mg/kg) as a positive control blocked
TCS significantly (see Figure 1, latency for ESM: 1800 ± 0 s,
n = 10, p < 0.001; mortality/total number = ESM: 0/10).
We found that the specific agonist of TRPV1 capsaicin (CAP,
40mg/kg) directly led to TCS without PTZ induction, and
most animals died (mortality/total number = 7/10) from TCS
during the first 5min after CAP injection (latency: 407.4 ±
232.22 s, n = 10). The latency to TCS induced by PTZ was
significantly delayed in lower doses of CAP (5 and 10mg/kg)
groups compared with the vehicle group (Figure 1A, vehicle
[VEH]: 217.56 ± 40.40 s, n = 9; 5mg/kg CAP [5 CAP]: 970.44 ±
185.77 s, n = 9, p = 0.006; 10mg/kg CAP [10 CAP]: 1227.56 ±
225.34 s, n = 9, p < 0.001), and there is no difference among
vehicle, 5, and 10mg/kg CAP groups in seizure development
[Figure 1B, F(2, 24) = 1.668, p = 0.210]. However, the mortality
(Figure 1C, mortality/total number = VEH: 4/9; 5 CAP: 6/9; 10
CAP: 5/9) was increased in both 5 and 10mg/kg CAP groups.
These results showed that activation of TRPV1 with lower dose
of CAP increased seizure severity although delayed the latency of
PTZ-induced TCS.
TRPV1 antagonist capsazepine (CPZ), a synthetic compound
as the structural analog to CAP molecule (Messeguer et al.,
2006), is extensively used as a competitive antagonist in phar-
macological studies (Maggi et al., 1993; Walpole et al., 1994;
Nguyen et al., 2010). The latency to TCS was significantly
increased in 0.05, 0.5, and 1mg/kg CPZ groups compared with
the vehicle group (Figure 1D, VEH: 408.4 ± 39.89 s, n = 10;
ESM: 1800 ± 0 s, n = 9, p < 0.001; 0.05mg/kg CPZ [0.05
CPZ]: 1148.50 ± 226.32 s, n = 10, p < 0.001; 0.5mg/kg CPZ
[0.5 CPZ]: 1508.56 ± 116.25 s, n = 9, p < 0.001; 1mg/kg CPZ
[1 CPZ]: 1243.78 ± 166.83 s, n = 9, p < 0.001). Although the
development of PTZ-induced seizures was no difference among
vehicle, 0.05, 0.5, and 1mg/kg CPZ groups [Figure 1E, F(3, 34) =
2.539, p = 0.073], the mortality was reduced in the 0.05 and
0.5mg/kg CPZ groups (mortality/total number = VEH: 4/10;
ESM: 0/9; 0.05 CPZ: 1/10; 0.5 CPZ: 1/9) but not in the 1mg/kg
CPZ group (mortality/total number = 4/9) (Figure 1F). These
results showed that systemic administration of the antagonist of
TRPV1 reduced seizure severity in a dose-dependent manner.
BOTH TRPV1 KNOCKOUT MICE AND HIPPOCAMPAL TRPV1
OVEREXPRESSION MICE EXHIBITED REDUCED SUSCEPTIBILITY TO
PTZ-INDUCED SEIZURES
As a competitive antagonist of TRPV1, CPZ may block other
voltage-activated calcium channels (Docherty et al., 1997). In
order to avoid the side interference factor of CPZ, we used
a transgenic mouse with TRPV1 knockout (Caterina et al.,
2000). As described in previous report (Caterina et al., 2000),
the TRPV1 gene was disrupted by deleting an exon encoding
part of the fifth and all of the sixth putative transmembrane
domains of the channel, together with the intervening pore-loop
region in the TRPV1 knockout mice. The mice lacking TRPV1
displayed reduced susceptibility to PTZ-induced seizures. The
latency to TCS was longer compared with the wild type (WT)
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FIGURE 1 | Systemic administration of TRPV1 agonist CAP increased the
severity of seizure while the antagonist CPZ reduced the susceptibility
to PTZ-induced seizures. (A) Injection of CAP (40mg/kg, i.p.) immediately
induced TCS even without PTZ induction. In contrast, the latency to TCS was
significantly delayed in 5, 10mg/kg CAP, and ESM groups compared with the
vehicle group. (B) Both 5 and 10mg/kg CAP had the tendency to increase the
grades of seizure except ESM compared with the vehicle group. (C) 5, 10,
and 40mg/kg CAP increased the mortality except ESM compared with the
vehicle mice. (D) The latency to TCS was significantly increased in 0.05, 0.5,
1mg/kg CPZ, and ESM groups compared with the control group. (E) 0.05,
0.5, and 1mg/kg CPZ had no effect on the grades of PTZ-induced seizures
except ESM. (F) 0.05, 0.5mg/kg CPZ, and ESM groups showed decreased
mortality but not in 1mg/kg CPZ group compared with the vehicle group. The
number in the bars of panel (C, F) represents the mice number of death or
survival, respectively. All data are expressed as mean ± SEM. ∗∗p < 0.01.
∗∗∗p < 0.001.
mice (Figure 2A, WT: 795.80± 176.70 s, n = 10; knockout [KO]:
1626.8 ± 116.18 s n = 10; p = 0.001). And the development of
PTZ-induced seizures [Figure 2B, F(1, 18) = 5.599, p = 0.029]
and mortality (Figure 2C, mortality/total number = WT: 4/10;
KO: 1/10) were both significantly decreased in TRPV1 knockout
mice. Consistent with the results of systemic TRPV1 antagonist
CPZ, these results suggested that the decrease of TRPV1 function
systemically reduced the susceptibility to PTZ-induced seizures.
However, opposite from results of systemic agonist capsaicin,
hippocampal TRPV1 overexpression mice exhibited reduced sus-
ceptibility to PTZ-induced seizures.
TRPV1 is expressed in the hippocampus, which plays a central
role in the generation and propagation of seizure (Wieshmann
et al., 1999). However, the role of TRPV1 in the hippocam-
pus in epileptogenesis in vivo has not yet been attempted. We
generated a transgenic mouse line by crossing ROSA-TRPV1
mice to CA1-Cre mice (as described previously in methods),
which overexpressed TRPV1 specifically in the hippocampus.
Our results showed that the hippocampal TRPV1 overexpres-
sion (OE)mice exhibited reduced susceptibility to seizure. Longer
latency to TCS (Figure 2D, WT: 274.40 ± 32.04 s, n = 10; OE:
1086.30 ± 242.55 s n = 9; p = 0.01) and decreased seizure devel-
opment [Figure 2E, F(1, 17) = 6.109, p = 0.024] were observed in
hippocampal OEmice compared with theWTmice, and themor-
tality (Figure 2F, mortality/total number = WT: 6/10; OE: 2/9)
induced by seizure was decreased in hippocampal OEmice. These
findings showed that increase of hippocampal TRPV1 would
protect animals away from PTZ-induced seizures, which also sug-
gested that TRPV1 in the hippocampus exerted an important role
in epilepsy.
HIPPOCAMPAL ADMINISTRATION OF TRPV1 AGONIST AND
ANTAGONIST REDUCED THE SUSCEPTIBILITIES TO PTZ-INDUCED
SEIZURES IN A DOSE-DEPENDENT MANNER
To further investigate the role of hippocampal TRPV1 in the
epilepsy, we administrated TRPV1 agonist CAP and antago-
nist CPZ directly into the hippocampus area. Here we found
that the latency to TCS was significantly delayed with intra-
hippocampal injection of 33 nmol/μL/side CAP compared with
the vehicle group (Figure 3A, VEH: 56.36 ± 1.77 s, n = 14;
10 nmol/μL/side CAP [10 CAP]: 230.58 ± 142.98 s, n = 12,
p = 0.505; 33 nmol/μL/side CAP [33 CAP]: 775.20 ± 223.78 s,
n = 15, p = 0.005; 100 nmol/μL/side CAP [100 CAP]: 515.12
± 280.62 s, n = 8; p = 0.122). The maximum seizure score
(Figure 3B, VEH: 4.93 ± 0.34; 10 CAP: 4.58 ± 0.47, p = 0.645;
33 CAP: 3.2 ± 0.54, p = 0.017; 100 CAP: 4.63 ± 0.63, p =
0.719) and the mortality (Figure 3C, mortality/total number =
VEH: 7/14; 10 CAP: 5/12; 33 CAP: 3/15; 100 CAP: 4/8) were
reduced after hippocampal administration of 33 nmol/μL/side
CAP. However, the behavioral performances of seizure were not
changed by CAP at the doses of 10 and 100 nmol/μL/side. On
the other hand, the latency to TCS was significantly delayed with
TRPV1 antagonist CPZ at the dose of 33 nmol/μL/side compared
with vehicle group (Figure 3A, 10 nmol/μL/side CPZ [10 CPZ]:
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FIGURE 2 | Decreased susceptibility to PTZ-induced seizures in TRPV1
knockout mice and hippocampal TRPV1 overexpression mice. (A) The
latency to TCS in the TRPV1 knockouts was delayed compared with WT
mice. (B) The development of seizure was reduced in TRPV1 knockout mice
than WT mice. (C) The TRPV1 knockout mice also showed decreased
mortality. (D) Longer latency to TCS of hippocampal TRPV1 overexpression
(OE) mice than WT mice. (E) Reduced seizure development of hippocampal
TRPV1 OE mice compared with the WT group. (F) Lower mortality in
hippocampal TRPV1 OE mice. All data are expressed as mean ± SEM.
∗p < 0.05. ∗∗p < 0.01.
479.15 ± 208.99 s, n = 13, p = 0.102; 33 nmol/μL/side CPZ [33
CPZ]: 1399.20 ± 287.78 s, n = 6, p < 0.001; 100 nmol/μL/side
CPZ [100 CPZ]: 135.25 ± 6.61 s, n = 4, p = 0.834). The maxi-
mum seizure score (Figure 3B, 10 CPZ: 3.15 ± 0.65, p = 0.018;
33 CPZ: 1.83 ± 1.17, p = 0.001; 100 CPZ: 6 ± 0, p = 0.323)
and the mortality induced by seizure (Figure 3C, mortality/total
number = 10 CPZ: 4/13; 33 CPZ: 1/6; 100 CPZ: 4/4) were
both decreased in the 10 and 33 nmol/μL/side CPZ groups, not
in 100 nmol/μL/side CPZ group. Hippocampal administration
of the therapeutic drug ESM had the tendency to increase the
latency to TCS (latency: 581.71 ± 314.73 s, n = 7, p = 0.091),
but could not alleviate the seizure development (seizure score:
4.29 ± 0.64, p = 0.467) and mortality (mortality/total number
= 2/7). It is possible that hippocampal administration of etho-
suximide (ESM), the positive control, lacked positive effects on
PTZ-induced seizures may be due to the unclear action mecha-
nism of ESM in different brain areas. It was concluded that both
agonist and antagonist of hippocampal TRPV1 were efficacious
in anti-seizure effects in a dose-dependent manner, which pro-
vided further evidence that hippocampal TRPV1 participated in
epileptogenesis.
THE CONFIRMATION OF GENETIC SYSTEM AND PTZ INDUCTION LED
TO THE ENHANCEMENT OF HIPPOCAMPAL TRPV1 EXPRESSION
We did detect the genotype of each mouse by PCR. And
we showed the genotyping of TRPV1 knockout mice and
hippocampal TRPV1 OE (Supplementary Figure 1). To further
verify our transgenic system, we detected TRPV1 expression in
hippocampus by RT-PCR analysis. The TRPV1 expression was
lacked in the hippocampus of TRPV1 knockoutmice (Figure 4A).
Meanwhile, hippocampal TRPV1 expression was significantly
enhanced in the hippocampal TRPV1 OE mice compared with
the wild type mice (Figure 4B, WT: 1 ± 0.13, n = 3; OE: 4.84 ±
0.31, n = 3, p < 0.001). These results confirmed that the genetic
system here worked well.
As mentioned above that alteration of hippocampal TRPV1
expression changed the susceptibility to PTZ-induced seizures,
we are wondering whether PTZ induction altered the expres-
sion of TRPV1 in hippocampus. We further used RT-PCR
to test the hippocampal TRPV1 expression after PTZ induc-
tion. The TRPV1 expression in hippocampus was significantly
increased after PTZ-induction compared with the vehicle treated
group (Figure 4C, VEH: 1 ± 0.33, n = 3; PTZ: 5.65 ± 1.9, n = 3,
p = 0.038), which is consistent with previous study in patients
(Sun et al., 2013).
Moreover, we used microinjection to administer 1μL/side
trypanblue into hippocampus to show the actual location of
rat hippocampus, and the location was corresponded to the
example picture from “The Rat Brain in Stereotaxic Coordinates”
(Figure 4D).
DISCUSSION
It is concluded that systemic or hippocampus-specific inter-
ference of TRPV1 altered the susceptibility of PTZ-induced
seizures in our present investigation. Systemic administration
of TRPV1 antagonist CPZ reduced the susceptibility of PTZ-
induced seizures in a dose-dependent manner while the agonist
increased the seizure severity although delayed the latency to
TCS. Furthermore, TRPV1 knockout mice exhibited decreased
susceptibility of PTZ-induced seizures. Interestingly, the reduced
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FIGURE 3 | The susceptibility to PTZ-induced seizures was reduced
after intra-hippocampal administration of TRPV1 agonist and
antagonist in a dose-dependent manner. (A) The latency to TCS was
significantly delayed in hippocampal administration of 33 nmol/μL/side
CAP, 33 nmol/μL/side CPZ groups compared with the vehicle group. The
10, 100 nmol/μL/side CAP; 10, 100 nmol/μL/side CPZ, and ESM had no
effect on the latency to TCS. (B) Similarly, the maximum grades of
seizure were significantly reduced by 33 nmol/μL/side CAP, and 10,
33 nmol/μL/side CPZ except 10, 100 nmol/μL/side CAP, 100 nmol/μL/side
CPZ, and ESM compared with the vehicle group. (C) Decreased mortality
in 33 nmol/μL/side CAP and 10, 33 nmol/μL/side CPZ groups. However,
the mortality were not changed by 10, 100 nmol/μL/side CAP,
100 nmol/μL/side CPZ, and ESM administration. All data are expressed as
mean ± SEM. ∗p < 0.05. ∗∗p < 0.01. ∗∗∗p < 0.001.
FIGURE 4 | The RT-PCR analysis of TRPV1 expression in hippocampus.
(A) The TRPV1 expression was lost in the hippocampus of TRPV1 knockout
mice compared with the wild type mice. (B) The RT-PCR revealed increased
expression of hippocampal TRPV1 in TRPV1 overexpression mice compared
with the wild type mice. (C) The hippocampal TRPV1 expression was
significantly increased in PTZ group compared with the vehicle group. (D)
Schematic diagram represented the drug injection location in hippocampus
(Top panel). The bottom picture was the representative section displaying the
location of drug injection in hippocampus by stained with trypanblue from a
typical rat. TRPV1: 415 bp; β-actin: 171 bp. All data are expressed as mean ±
SEM. ∗p < 0.05. ∗∗∗p < 0.001.
susceptibility of PTZ-induced seizures was also observed in hip-
pocampal OE mice. In addition, hippocampal administration
of TRPV1 agonist or antagonist reduced the susceptibility to
PTZ-induced seizures. Taken together, our findings support that
systemic administration of TRPV1 antagonist may be a novel
therapeutic target for epilepsy, and hippocampal TRPV1 plays an
important role in epileptogenesis.
Our present results showed that systemic administration of
TRPV1 agonist CAP at high dose (40mg/kg) directly induced
TCS without PTZ induction, and most of the animals died at
the first 5min after CAP injection. It is supposed that exces-
sive activation of TRPV1 may lead to cytotoxicity and neuronal
death process (Shirakawa et al., 2008; Davies et al., 2010), thus
high dose CAP may directly produce the onset of seizure. In
addition, we showed that the lower doses of CAP increased the
severity of PTZ-induced seizures, which was similar with previous
reports (Manna and Umathe, 2012; Gonzalez-Reyes et al., 2013).
However, opposite from results of systemic CAP, direct admin-
istration of TRPV1 agonist CAP into hippocampus decreased
seizure severity, which may be resulted from the desensitization
of hippocampal TRPV1 by CAP. Iannotti et al. found that CAP
reduced both epileptiform burst amplitude and duration in hip-
pocampal brain slices exposed to Mg2+-free solution by TRPV1
de-phosphorylation and desensitization (Iannotti et al., 2014).
Furthermore, various types of TRPV1 expressing cell showed dif-
ferent desensitization patterns by CAP (Czikora et al., 2013), the
different effects of TRPV1 on different brain regions were inte-
grated in the systemic administration, which may explain for
the increased seizure severity in systemic CAP administration
experiment. Thus it is understandable the inconsistent results
from systemic and hippocampal injection of TRPV1 agonist. The
delayed latency but increased severity of PTZ-induced TCS in
lower doses of systemic CAP experiment may be caused by the
desensitization upon activation (Figure 1). The effects of TRPV1
agonist on epilepsy will be studied further in consideration of
TRPV1 desensitization and its different effects on various brain
areas in future research.
It has been reported that TRPV1 is expressed at relatively
high level in the human hippocampus (Mezey et al., 2000; Sun
et al., 2013), a focus of seizure generation and propagation
(Wieshmann et al., 1999). The expression of TRPV1 protein
was significantly increased in the hippocampus and cortex of
subjects with epilepsy (Bhaskaran and Smith, 2010; Sun et al.,
2013). Similarly, our RT-PCR results revealed that PTZ-induced
seizure increased hippocampal TRPV1 expression (Figure 4C).
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Hippocampal TRPV1 OE mice showed increased quantity of
TRPV1 expression in the hippocampus (Figure 4B), which may
increase neuronal excitability via the enhanced influx of calcium.
However, we did not observe any sign of spontaneous seizure
in these mice, which indicated that homeostatic regulation of
intrinsic excitability has been established in hippocampal TRPV1
OE mice. To be notified that opposite from results of systemic
agonist CAP, hippocampal TRPV1 OE mice exhibited reduced
susceptibility to PTZ-induced seizures. We speculated that due to
the ceiling effect of overexpressed hippocampal TRPV1 in these
mice, PTZ induction could not further increased TRPV1 expres-
sion and excitability in hippocampus, which may explain for the
decreased susceptibility to PTZ-induced seizure in hippocam-
pal TRPV1 OE mice. Furthermore, it was also supposed that
TRPV1 may predominantly overexpress on GABA-interneurons
thus reduced the excitability. Therefore, the cellular specific dis-
tribution of TRPV1 expression needs to be clarified in future
research.
Several findings indicated that TRPV1 antagonist reduced
the propagation of epileptiform activity (Gonzalez-Reyes et al.,
2013) and prevented the PTZ-induced seizures (Manna and
Umathe, 2012). In our investigation, systemic administration of
TRPV1 antagonist CPZ significantly delayed the latency to TCS
and decreased the mortality induced by seizure (Figures 1D–F),
which was consistent with previous study (Manna and Umathe,
2012). Furthermore, we introduced TRPV1 knockout mice
(Caterina et al., 2000) to further determine its function in
epilepsy. Kong et al. previously reported that lack of TRPV1
attenuated the severity of PTZ -induced seizures (Kong et al.,
2014). Consistent with this report, we also observed that the
mice lack of TRPV1 displayed longer latency to TCS, reduced
seizure development and mortality (Figures 2A–C). Both results
from CPZ administration and knockout mice showed that sup-
pression of TRPV1 function prevented PTZ-induced seizures. It
was unfortunate that we did not obtain a conditional hippocam-
pal TRPV1 knockout mouse line. However, we have injected
TRPV1 antagonist CPZ into hippocampus, and found that sup-
pression of hippocampal TRPV1 delayed the latency to TCS,
reduced the development of seizure and mortality in a nice dose-
dependent manner (Figures 3A–C). Here we firstly reported that
suppression of hippocampal TRPV1 reduced the susceptibility to
PTZ-induced seizures. Combined with the results from systemic
administration of TRPV1 antagonist and TRPV1 knockout mice,
we demonstrated that the suppression of function of TRPV1
exerted an anti-seizure property.
CONCLUSIONS
In this investigation, we found that suppression of TRPV1 by
systemic or hippocampal administration of antagonist or lack
of TRPV1 reduced the susceptibility to PTZ-induced seizures.
Furthermore, hippocampal administration of TRPV1 agonist and
hippocampal TRPV1 OE mice exhibited decreased susceptibil-
ity of seizure, although the systemic administration of TRPV1
agonist led to increased seizure severity. Therefore, it remains
to be further studied the underlying mechanism of hippocam-
pal TRPV1 function in epilepsy. In summary, our results indi-
cate that systemic administration of TRPV1 antagonist may be
a new potential therapeutic target for epilepsy treatment, and
hippocampal TRPV1 exerts important role in epilepsy.
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Supplementary Figure 1 | Genotyping of TRPV1 knockout mice and
hippocampal TRPV1 overexpression mice. (A) The genotype of TRPV1
knockout mice. Mutant = 600 bp; Heterozygote = 600 bp and 984 bp;
Wild type = 984 bp. (B) The hippocampal TRPV1 overexpression mice
were crossed by CA1-Cre (top panel) with ROSA26-TRPV1 (bottom panel)
mice, both of which were genotyped by specific primers respectively.
Positive Cre = 300–400 bp; Negative Cre = no band. ROSA-TRPV1:
Mutant = 600bp; Heterozygote = 600bp and 482bp; Wild type =
482 bp.M = Mutant; W = Wild type; H = Heterozygote; P = Positive Cre;
N = Negative Cre.
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